Investors & Media
Company Overview
View All
LyGenesis’s cell therapies are engrafted using endoscopic ultrasound procedure, which is associated with decreased medical risks and costs relative to full organ transplantation. Our pipeline of therapies target a variety of unmet needs, including end stage liver disease, Type 1 diabetes, end stage renal disease, aging, and autoimmune disorder.
Insights Corner
LyGenesis is Pioneering Organ Regeneration in Pittsburgh
Pittsburgh Region Video Jul 26, 2021
Lygenesis, a University of Pittsburgh life sciences spinout, is using cell therapy technology to transform the methodology behind the science of organ transplantation, thanks to experts like Michael Hufford.